Rockwell Medical Announces Transformational Global Hemodialysis Acquisition - ROCKWELL MEDICAL INC

Financial Performance:

• The combined entity is projected to generate annual revenue between $400 million and $450 million, with approximately 90% forecasted as recurring revenue.
• The base purchase price for Vantib's business is $125 million, subject to customary adjustments.
• Financing structure includes $100 million in two term loans (Tranche A: 6 years at SOFR + 550 bps; Tranche B: 6 years at SOFR + 700 bps) and a $25 million convertible note.
• Vantib may receive up to $45 million in contingent consideration tied to revenue and EBITDA milestones over several years.
• Rockwell Medical withdrew its 2026 guidance for net sales, gross margin, adjusted EBITDA, and operating cash flow due to expected transaction-related expenses in Q3 and Q4.
• Management anticipates the acquired product groups have similar current gross margins to Rockwell, with potential for accretion post-integration.
• Pro forma liquidity is deemed sufficient to support operations between signing and closing without additional capital raises.

Guidance and Future Outlook:

• The acquisition is expected to close in mid-2027, pending regulatory approvals and other closing conditions.
• This transaction accelerates Phase 2 of Rockwell's three-phase turnaround strategy, rapidly transitioning the company from a U.S.-based concentrate supplier to a globally scaled hemodialysis leader.
• Post-closing, the company plans to leverage the 100,000-machine installed base to expand recurring revenue through consumables, parts, and technical services.
• Future focus includes cross-selling Vantib's machine and water treatment products into Rockwell's existing U.S. customer base, which management views as a significant growth opportunity.
• The Medulla, Italy manufacturing campus is slated to become a "center of excellence" for global product development and manufacturing.

Business Segments and Product Lines:

• Rockwell will expand from a pure-play concentrates business to a vertically integrated platform including dry concentrate cartridges, hemodialysis machines (AK-98), water treatment systems (CWP-100, CWB-800), and technical services.
• The acquisition adds 1 million square feet of state-of-the-art manufacturing capacity in Medulla, Italy, located within the Mirandola biomedical district.
• The portfolio now covers the entire hemodialysis treatment ecosystem, reducing reliance on concentrates alone and adding durable aftermarket revenue streams.
• Existing U.S. concentrate manufacturing lines are continuing to ramp up, creating a combined manufacturing network enhancing global scale and efficiency.

Market and Competitive Landscape:

• The combined company targets a global footprint covering over 35 territories, significantly expanding beyond Rockwell's current U.S.-centric position.
• Major global competitors identified include Fresenius and Nipro, particularly in international government tender markets.
• Rockwell gains immediate access to established customer relationships, distribution channels, and technical expertise in Canada, Europe, and the Asia-Pacific region.
• The acquisition provides 100,000 installed hemodialysis machines, creating a platform for cross-selling and expanding market share in existing customer centers.
• The strategy focuses on leveraging government tenders already secured by Vantib in the acquired territories.

Risks and Challenges:

• Primary risk is the execution of the acquisition, which requires specific regulatory approvals and the satisfaction of closing conditions before mid-2027.
• Integration challenges include aligning operations, systems, and cultures between Rockwell and Vantib across multiple geographies.
• Financing obligations rely on the combined business generating sufficient cash flow; failure to meet revenue milestones could impact contingent consideration payments.
• Interest rates on term loans are structured to increase annually (75 bps per year), creating future financing cost risks.
• Management notes no immediate liquidity risks but acknowledges the complexity of maintaining continuity of supply and technical support during the transition.

Management Commentary and Tone:

• Management expressed high confidence, describing the transaction as "transformational" and "incredibly exciting."
• CEO Mark Strobeck emphasized that the deal transforms Rockwell's scale, scope, and strategic profile while remaining firmly centered on the core hemodialysis market.
• CFO Jesse Neary confirmed the company is sufficiently funded to navigate the pre-close period without additional capital.
• The tone highlighted a disciplined approach to the transition, prioritizing customer continuity, employee retention, and supply chain reliability.
• Management indicated a willingness to work closely with the Vantib team to build a comprehensive integration plan.

Analyst Questions and Answers:

• Liquidity: Asked if additional capital is needed for integration; answered that Rockwell is sufficiently funded for the interim period, with potential for beneficial financing structures post-close.
• Commercial Relationships: Clarified that a post-closing commercial relationship will exist where Rockwell supplies Vantib and Vantib may remain a customer; also noted Vantib's products are similar to Rockwell's concentrates.
• Cross-Selling: Addressed opportunities to introduce Vantib's machine and water systems to Rockwell's U.S. base, which management deemed "significant."
• Margins: Confirmed acquired product margins are similar to Rockwell's current levels, with upside potential post-integration.
• Competition: Identified Fresenius and Nipro as key global competitors; noted Vantib's advantage in existing government tenders across 35+ territories.
• Integration: Management stated that Vantib's Medulla team, comprising experienced professionals, will join Rockwell, and the facility will be enhanced as a center of excellence.

Other Key Points:

• Transition service agreements, manufacturing agreements, and supply agreements will be in place between signing and closing to ensure operational continuity.
• The acquired business includes a global technical services team and a 100,000-unit installed machine base, which drives ongoing demand for consumables and parts.
• Rockwell Medical is currently not answering questions regarding its prior quarterly financial performance (three and nine months ended September 30, 2026); those will be addressed on November 12th.
• The acquisition is strictly an expansion of the core hemodialysis business, not a diversification into unrelated therapies.